Pataginis is right. There is some additional risk but if UK/EU/Korea approve then HGEN can skip the US and the FDA. There will be a place for all the product and even with the EUA issue, he still has a target of $28.
Worse case, listening to the call yesterday there appears to be no shortage of potential demand for our mab manufacturing.
Smart money will come back in for CDMO. And the ACTIV 5 trial for HGEN should be close to fully enrolled and the treatment plan look is 28 days. So not a long way off to prove the safety and efficacy.
Market Data 
Markets 
AI
